Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: Pharma - What They Never Told You

F&O Talk: Nifty to remain rangebound, says Sudeep Shah; picks 8 stocks for next week

Indian stock markets concluded the week with modest gains, as Sensex and Nifty erased earlier surges on monthly expiry day. Analysts observe Nifty's consolidation, with key support at 23,750-23,800 and resistance at 24,250-24,300. Bank Nifty shows outperformance, eyeing 58,800 for further upside. Derivatives data suggests improving sentiment, with FIIs reducing…

The Economic Times

Pharma, power & mid-sized banks: Where Mayuresh Joshi is putting money to work right now

Indian markets are showing signs of recovery as geopolitical tensions ease, paving the way for a stronger earnings outlook in the second half. While Q1 may be challenging due to supply chain issues and inflation, strategist Mayuresh Joshi advises investors to look beyond the near-term. He favors pharma, domestic engineering,…

The Economic Times

'Not a great environment for Indian market': Harsha Upadhyaya on Iran-US tensions, IT outlook, pharma bet, and where to be cautious

Global challenges are impacting Indian stocks. West Asian tensions and rising US inflation create headwinds. Tech sector shifts also affect markets. Kotak AMC's Chief Investment Officer advises caution. Pharma and healthcare offer a defensive haven. Metals require trimming positions. IT services face structural slowdowns. Foreign investor flows remain a key…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

FII exodus, crude shock, and Rupee under pressure: Deepak Shenoy breaks down India's market storm

Indian stock markets are facing tough times due to global economic factors. Deepak Shenoy of Capitalmind MF advises investors to look beyond immediate market swings. He highlights that while foreign investors are pulling money out, domestic flows are providing support. Shenoy suggests focusing on sectors like Pharma for defensive plays.

The Economic Times

Dalal Street Week Ahead: Nifty stuck in consolidation zone; 23,800 remains key breakout hurdle

Markets experienced volatility and ended the week with a modest loss, primarily due to MSCI rebalancing flows. Nifty consolidated within a range, with immediate resistance at 23,800 and support at 23,300-23,400. Traders are advised to maintain a selective approach and protect gains.

The Economic Times

Nifty IT bottoming out? Anand James on the expiry outlook, pharma profit-booking, and 2 stocks to buy this week

Geojit Investments’ Anand James expects Nifty to attempt a range breakout above 23,700 during the monthly expiry week. He highlighted early bottoming signs in the Nifty IT index, warned of near-term profit booking in Pharma stocks, and shared bullish technical views on Surya Roshni and Cholamandalam Investment for short-term trading…

The Economic Times

God Is Watching: Namita Hits Back at Trolls

What makes someone stop in the middle of a busy morning just to speak? Not anger. Not attention. But a limit. When respect is crossed, silence no longer feels right. That’s exactly what happened with Namita Thapar. A simple video about wellness turned into weeks of trolling, slowly turning personal.…

MyLifeXP

Read news from The Economist, FT, and more,
with one subscription

From Legacy Systems to AI Ready Ecosystems in Global Life Sciences

Sujit Murumkar is a visionary leader who designed and implemented enterprise scale modern data ecosystems for one of the largest pharmaceutical organization, describing the digital transformation facing life sciences companies worldwide.

International Business Times

Analysis: Trump's trade and tax policies set to widen EU-US innovation gap in 2026

Companies say the EU’s deregulation efforts are insufficient against Trump's “carrot-and-stick” strategy of pairing generous US tax incentives with a punitive 15% tariff on imports from the EU.

Euronews

RFK Jr. sends ‘thousands of letters’ to drug companies over ‘misleading’ ads that ‘distorted physician prescribing habits’

Those happy pill ads with dancing patients? Trump's administration says they're basically lying to you.

We Got This Covered

'Pharma Bro' CEO Jacked Price of A Life-Saving Drug From $13.50 to $750 Per Pill Overnight — And His Reason? 'We Needed to Turn a Profit'

Imagine needing a medication that costs less than a fast-food meal—only to wake up the next day and find it's suddenly priced like a luxury car payment…per single pill.

Benzinga

Laura Loomer’s MAGA critics accuse her of being funded by Big Pharma

‘I do not work for Big Pharma. I work in support of President Trump on the outside of the administration,’ Loomer tells The Independent

The Independent UK

Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills

Imagine this: a hospital conference room, lights low, filled with decision-makers. A sales representative clicks through slides driven by Palantir Technologies’ (NASDAQ:PLTR) Foundry platform, highlighting real-time data integration and pinpoint analytics that would make Pharma RD from the past look like it’s still sending lab results by fax. Down the…

Benzinga

Thomas Massie's New Bill Would Let People Sue Pharma for COVID Vaccine Injuries

Federal liability protections currently prevent people suing COVID-19 vaccine makers, and instead require them to request compensation from a program that's covered only 39 COVID vaccine injury claims.

Reason

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Evoke Pharma (EVOK) Shares Skyrocket On New Patent: What's Going On?

Shares of Evoke Pharma Inc (NASDAQ:EVOK) are trading sharply higher Wednesday morning after the specialty pharmaceutical company announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering its lead product, GIMOTI.

The Independent UK

Former CDC nominee goes scorched earth, blaming two Republicans and ‘big Pharma’ for failed bid

Weldon’s nomination to head the CDC was withdrawn just 12 hours before he was supposed to testify to the Senate health committee

Fortune

My son’s rare disease diagnosis spurred me to ditch Big Pharma for a biotech startup

Most individuals diagnosed with a rare disease won’t live to become teenagers or adults. I knew what I had to do.

The Independent UK

£20m initiative to tackle ‘historically low’ numbers in dementia clinical trials

The Dementia Trials Accelerator will allow ‘tens of thousands’ to take part in trials.

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Doctors rarely understand how influence really works. The result: an NHS bowing to the needs of big pharma

There must be transparency over funding to medics from the pharmaceutical industry – and that’s only the start, says the GP and writer Margaret McCartney

Woman & Home

Sienna Miller’s £19 French skincare secret to achieving a glowing complexion

Sienna Miller has hailed this affordable retinol cream as the "French secret to great skin" and is a must-have in your beauty bag...

Fortune

'Pharma Bro' behind DJT crypto token, no proof Barron Trump involved

A Twitter sleuth exposed Martin Shkreli's ties to DJT, an unauthorized Trump memecoin.

The Hindu

30-year-old worker dead, about eight employees injured when Pharma bus hits stationed lorry at Lankelapalem

30-yr-old worker dies, 8 injured in Anakapalli road accident. Cause suspected to be overspeeding. Unauthorised parking of lorries alleged to be cause of accidents. Family of deceased demands compensation.

StockNews.com

Under $15 Bargains: 3 Pharma Stocks to Watch

The pharmaceutical industry is anticipated to remain resilient, owing to increasing healthcare expenditure. Given this backdrop, it could be wise to watch quality pharma stocks Organon & Co. (OGN), GoodRx Holdings (GDRX), and Viatris (VTRS) trading under $15 now. Read on….

Chicago Sun-Times

Fast-paced ‘Painkiller’ depicts the making, selling and often devastating effects of OxyContin

Netflix limited series recounts Purdue Pharma’s work on the addictive drug from the perspective of its leader, some sellers, an investigator and a victim.

Reason

Did Fox Really Fire Tucker Carlson for Crossing the 'Red Line' of Criticizing Big Pharma, as RFK Jr. Claims?

If so, the network failed to enforce the supposed rule before and after cancelling its top-rated host.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.